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Direct-acting antiviral medications (DAAs) have revolutionized care for hepatitis C positive (HCV+) liver 
(LT) and kidney (KT) transplant recipients. SRTR registry data were integrated with national 
pharmaceutical claims (2007-2016) to identify HCV treatments before 1/2014 (pre-DAA) and after (post-
DAA), stratified by donor (D) and recipient (R) serostatus and payer. Pre-DAA, 18% of HCV+ LT recipients 
were treated within 3 years and without differences by donor serostatus or payer. Post-DAA, only 6% of 
D-/R+ recipients, 19.8% of D+/R+ recipients with public insurance, and 11.3% with private insurance 
were treated within 3 years (P<0.0001). Liver transplant recipients treated for HCV pre-DAA experienced 
higher rates of graft loss (adjusted hazard ratio [aHR] 1.341.852.10,  P<.0001) and death (aHR 1.471.681.91,  
p<0.0001). Post-DAA, HCV treatment was not associated with death (aHR 0.340.671.32, p=0.25) or graft 
failure (aHR 0.320.641.26, p=0.20) in D+R+ LT recipients. Treatment increased in D+R+ KT recipients (5.5% 
pre-DAA vs. 12.9% post-DAA), but did not differ by payer status. DAAs reduced the risk of death after 
D+/R+ KT by 57% (0.190.430.95,  p=0.04) and graft loss by 46% (0.270.541.07
 
, p=0.08). HCV treatment with 
DAAs appears to improve HCV+ LT and KT outcomes; however, access to these medications appears 





Direct-acting antivirals (DAAs) have dramatically altered the care of patients with chronic hepatitis C 
virus (HCV) infection.1-6 For the last two decades, chronic HCV infection was the leading indication for 
liver transplant (LT) in the United States. Treatment of HCV infection prior to 2014 consisted primarily of 
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debilitating side effects, and, generally, were contraindicated in patients with decompensated cirrhosis 
or, in the case of ribavirin, advanced chronic kidney disease (CKD).7,8 DAAs reduce morbidity and result 
in sustained virological response 12 weeks after completing treatment (SVR12) rates greater than 94% 
for most genotypes in both compensated and decompensated patients.4,9,10 DAAs have also been safely 
used in the post LT setting to prevent recurrent inflammation and fibrosis, which was universal in the 
absence of effective pretransplant treatment. Historically, recurrence of HCV in the liver graft resulted in 
cirrhosis in 20%-30% of LT recipients and fibrosing cholestatic hepatitis C in 2%-9% within the first 12 
months.11,12 DAAs have been shown to achieve SVR12 after LT in multiple clinical trials, although the 
impact of DAAs on longer-term liver and kidney transplant outcomes has not been reported.12
Among patients with end-stage renal disease (ESRD), HCV prevalence is 5 times greater than in 
the general population.
 
13,14 Historically, HCV-infected ESRD patients on dialysis were 60% more likely to 
die than their non-infected counterparts. Prior to DAAs, interferon-based regimens had low levels of 
efficacy and high rates of intolerability in this population and were generally contraindicated in HCV-
infected kidney transplant (KT) recipients owing to unacceptable rates of rejection and allograft 
dysfunction. Because most HCV-infected KT recipients in the pre-DAA era were therefore either 
untreated or intolerant to pre-transplant interferon/ribavirin, these patients experienced higher rates of 
graft loss and death than non-infected patients.15 In contrast, DAAs are both safe and well tolerated in 
patients with advanced chronic kidney disease (CKD), with SVR12 rates from 95-98%.16,17 DAA treatment 
in KT recipients successfully eradicates the virus without negatively affecting graft function in clinical 
series.18,19
While DAA treatment is revolutionary, access to it has been hampered nationally by its high 
cost.
  
20-22 Initial regimens resulted in total health care expenditures exceeding $100,000 USD (United 
States Dollars) per treatment course. As more DAAs have entered the market and competition has 
increased, costs have diminished, but remain in excess of $25,000 per course, depending on specific 
agent. Consequently, major private payers developed preauthorization processes that initially restricted 
use to patients with defined clinical conditions such as demonstrated hepatic fibrosis, cirrhosis, or 
advanced kidney disease, despite evidence suggesting clinical benefits even in patients without 
advanced liver disease.23 While long-term economic analyses suggest that DAAs are cost effective, few 
are cost saving despite reducing the need for transplant.24-26
While clinical trial experience with DAAs in the posttransplant LT and KT populations have 
demonstrated high SVR rates, no large-scale, population-based assessment of access to DAA treatment, 
effects on longer-term transplant outcomes, or increases in the cost of treatment has been conducted. 
Using a unique data set linking pharmacy claims data and transplant registry outcomes, we developed a 
 Furthermore, the cost savings are accrued 
far in the future when many patients have changed health insurance, diminishing enthusiasm for 
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national cohort of HCV-positive transplant recipients with sufficient power to assess DAA use in LT and 
KT recipients before and after introduction of DAAs, characteristics associated with posttransplant HCV 




We conducted a retrospective cohort study using linked health care databases in the US to ascertain 
patient characteristics, pharmacy fill records, and outcome events for LT and KT recipients. This study 
used transplant data from the Scientific Registry of Transplant Recipients (SRTR). The SRTR system 
includes data on all donors, waitlisted candidates, and transplant recipients in the US, submitted by the 
members of the Organ Procurement and Transplantation Network (OPTN). The Health Resources and 
Services Administration (HRSA), US Department of Health and Human Services, provides oversight of the 
activities of the OPTN and SRTR contractors. Baseline demographic information ascertained for LT and 
KT recipients from OPTN included age, sex, and race as reported by the transplant centers. 
Data sources 
Pharmacy fill data were assembled by linking SRTR records for LT and KT recipients with billing 
claims from a large US pharmaceutical claims data (PCD) warehouse that collects prescription drug fill 
records including self-paid fills and those reimbursed by private and public payers. PCD comprises 
National Council for Prescription Drug Program format prescription claims aggregated from multiple 
sources including claims warehouses, retail pharmacies, and prescription benefit managers for 
approximately 60% of US retail pharmacy transactions. Individual claim records include the pharmacy fill 
date with the national drug code identifying agent and dosage. After Institutional Review Board and 
HRSA approvals, PCD records were linked with SRTR records for transplant recipients. We applied a 
deterministic de-identification strategy wherein patient identifiers (last name, first name, date of birth, 
sex, and ZIP code of residence) were transformed before delivery to the Saint Louis University 
researchers with Health Information Portability and Accountability Act and Health Information 
Technology for Economic and Clinical Health (HITECH) -certified encryption technology from PCD. The 
patient de-identification software employs multiple encryption algorithms in succession to guarantee 
that the resulting “token” containing encrypted patient identifiers can never be decrypted. However, 
the algorithm yields the same results for a given set of data elements, such that linkages by unique 
anonymous tokens are possible.27
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We identified adult LT and KT recipients (age ≥18 years) with SRTR records of transplants between 2007 
and 2016 and available pharmaceutical fill records for up to 36 months posttransplant. Recipient clinical 
and demographic characteristics, characteristics of the donated organ, and other transplant factors 
including ischemic time and sharing, were defined by the OPTN Transplant Candidate and Recipient 
Registration forms (Table 1). Patients were identified has being HCV+ based on HCV serostatus at the 
time of transplant as noted on the Transplant Recipient Registration (TRR) form. As patients who were 
HCV antibody positive but nucleic acid testing (NAT) negative may be classified as positive on the TRR, 
we further identified patients who were given an HCV antibody or NAT-positive donor organ as evidence 
of an active viremic state (as use of HCV+ organs in NAT-negative recipients remains uncommon). 
Patient insurance coverage was dichotomized as public (Medicaid, Medicare, self-pay) vs. private (all 
others). Patient and graft outcomes were determined from SRTR registry data. 
 
Using pharmacy fill records, we identified claims for approved HCV medications and combinations. In 
the pre-DAA era, defined as before January 2014, HCV treatment was defined as pegylated interferon, 
interferon, and ribavirin. DAA-era HCV treatments, with or without ribavirin, are shown in Table S1.  
HCV Medication 
 
Demographic characteristics: Donor and recipient characteristics were drawn from the SRTR data. Pre- 
and post-DAA-era differences were assessed using Student t-test and chi-squared analyses as 
appropriate.  
Analyses 
Propensity to receive HCV treatment: Kaplan-Meier survival analysis was performed to identify the 
proportion of patients receiving HCV treatment by era and primary payer. Multivariate regression 
analyses were separately performed for LT and KT recipients to assess factors correlated with HCV 
treatment before and after introduction of DAAs. Donor and recipient characteristics, including primary 
payer, were included as independent variables. 
Cost of treatment analysis: The direct cost of HCV treatment was calculated using pharmacy claims for 
LT and KT recipients before and after introduction of DAAs. 
Survival analysis: Posttransplant survival was assessed in HCV+ patients who did and did not receive HCV 
treatment in the pre- and post-DAA eras. Multivariate Cox proportional hazard models were constructed 
with HCV treatment as a time-varying covariate. Models were separately constructed for patients noted 
to be HCV+ on the TRR and for HCV+ patients who received HCV+ donor organs. Donor and recipient 
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Statistical significance: For all models, P<0.05 was used to determine statistical significance. Analyses 
were conducted using SAS version 9.4, Cary, NC.  




Between 2007 and 2016, there were 58,509 LTs were performed; pharmacy claims data for at least 1 
year after transplant were available for 41,690 (71%) of these (Table 1). Among patients with claims, 
15,671 (38%) were HCV donor negative and recipient positive (D-/R+), 1,468 (3.5%) were D+/R+, and 47 
(0.1%) were recorded as D+/R-. In the same period, 157,873 KTs were performed; pharmacy claims data 
were available for 121,800 (71%). In this population, 3,681 (3.0%) were D-/R+, 1,738 (1.4%) were D+/R+, 
and 294 (0.2%) were D+/R-.  
 
Use of HCV medications: Overall, 12.9% of patients undergoing LT received HCV medications within 3 
years after transplant. Among serologic subgroups, treatment prevalence varied from 0.75% of HCV D-
/R- patients to 35.2% of D+/R+ patients (Figure 1A). In the pre-DAA era, 4.0% of HCV D+/R+ and 5.5% of 
D-/R+ received HCV treatment within 1 year. Post-DAA, 13.5% of D+/R+ patients and 4.4% of D-/R+ 
patients received treatment within 1 year. By 3 years, 17.0% D+/R+ and 17.1% D-/R+ patients received 
treatment in the pre-DAA era. Post-DAA, 15.3% of D+/R+ and 5.5% of D-/R+ recipients had received 
treatment at the end of follow-up (2.3 years and 2.6 years, respectively). Clinical factors associated with 
use of HCV treatments pre-DAA include male sex (adjusted hazard ratio [aHR] 0.830.911.00), diabetes (aHR 
0.800.890.98), hypertension (aHR 1.031.131.25), higher model for end-stage liver disease (MELD) score (15-
30, aHR 1.011.101.20; >30, aHR 1.001.181.38 vs MELD<15), and black race (aHR 0.720.810.90). Post-DAA, donor 
HCV+ status (aHR 1.661.952.29), higher MELD score (15-30, aHR 1.231.421.65; >30, aHR 1.431.812.28), and 
black race (aHR 0.650.790.96
The impact of payer on LT recipient access differed by DAA era. Pre-DAA, HCV+ LT recipients 
with private insurance were equally likely to be treated with HCV medications (Figure 2A). After 
adjustment for donor and recipient characteristics, HCV+ recipients with private insurance were 
somewhat more likely to be treated (aHR 
) were associated with the likelihood of HCV treatment (Table S2A). 
1.011.101.19). However, in the post-DAA era, both D+/R+ and D-
/R+ recipients with private insurance were significantly less likely to receive HCV treatment (Figure 2B). 
Nearly 20% of D+R+ recipients with public insurance, compared with 11% of recipients with private 
insurance (P<0.0001), received treatment. After adjustment for other donor and recipient 
characteristics, D+/R+ recipients with private insurance were 45% less likely than publicly insured 
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public insurance received DAA treatment, compared with 5.0% with private insurance (aHR 0.740.840.96
As expected, HCV treatment was substantially less common in KT recipients; overall, 1.4% 
received HCV treatments within 3 years of transplant. Utilization was highest, at 22.8%, for D+R+ 
recipients; 11.3% of D-/R+ recipients received treatment (Figure 1B). Pre-DAA, 2.8% of D-/R+ and 5.5% 
of D+R+ recipients received treatment with HCV medications within 3 years. Post-DAA, 3.9% of D-/R+ 
and 12.9% of D+/R+ recipients received treatment (P<.0001). Differences by payer in the post-DAA era 
were modest. Among D+R+ recipients, 13.5% with public insurance received treatment compared with 
11.5% with private insurance (p=0.35). Among D-/R+ recipients, 4.3% with public insurance received 
treatment, compared with 2.9% with private insurance (p=0.05). Adjustment for donor and recipient 
characteristics, there were HCV treatment in R+ KT patients was more likely with D+ (Pre-DAA: aHR 
, 
p=0.01). 
1.432.02 2.84 vs. Post DAA aHR: 2.312.93 3.71
 
). In the post-DAA era, other patients whose race with not black 
or white and older patients were more likely to be treated. (Table S2b).  
Impact of HCV treatment on patient and graft survival: LT outcomes among all HCV+ recipients have 
improved in the post-DAA era (Figure 3A). Among all HCV+ LT recipients, after adjustment for donor and 
recipient characteristics, HCV requiring treatment pre-DAA was associated with a significantly higher risk 
of posttransplant mortality (aHR 1.471.681.91, p<0.0001) and all cause graft failure (aHR 1.641.852.10, 
p<.0001) (Figure 4A). In contrast, there was not increased risk of death or graft failure post-DAA (aHR for 
death: 0.740.941.19, p=0.61; aHR for graft failure: 0.740.941.19, p=0.62) (Figure 4; Table S3A). In D-/R+ 
recipients, HCV treatment pre-DAA was not associated with an increased risk of death (p=0.96) or graft 
failure (p=0.40). Among D+/R+ post-DAA, the reduction in the risk of death (aHR 0.340.671.32, p=0.25) and 
graft failure (aHR 0.320.641.26
Among HCV+ KT recipients, there was no significant improvement in unadjusted patient survival 
post-DAA compared with pre-DAA (Figure 3B). In the adjusted analysis, pre-DAA HCV treatment was 
associated with a non-statistically significant increased risk of death (aHR
, p=0.20) within three years of transplant was not statistically significant. 
(Table S3B). 
0.67 1.804.87, p=0.25) and graft 
failure (aHR 0.711.613.62, p=0.24) (Figure 4B; Table S4A). There was a non-significant protective effect of 
treatment for KT recipients post-DAA for mortality (aHR 0.370.661.18, p=0.16) and graft failure (aHR 
0.490.791.27, p=0.33) (Table S3; Table S4A).  Among D+R+ KT recipients, DAA treatment was associated 
with non-significant reduction in graft failure (aHR 0.270.54 1.07, P=0.08) and a statistically significant 
lower risk of death after KT (0.190.430.95
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The cost of HCV treatment increased dramatically for LT and KT recipients in the DAA era. The mean 
direct cost of HCV treatment for D+R+ recipients after LT increased from $9,772 USD pre-DAA to 
$120,096 USD in 2014-2017 (p<.0001. For KT, cost of treatment increased from $4,489 USD to $106,747 
USD (p<0.0001).  
DISCUSSION 
Introduction of DAAs has markedly improved care for LT and KT recipients with chronic HCV infection. 
Among LT recipients, our data support findings from smaller clinical studies that suggest that DAAs in 
the posttransplant setting improves posttransplant outcomes. In the pre-DAA era, HCV reinfection after 
LT was universal and treatment was generally reserved only for recipients with early aggressive 
recurrence resulting in fibrosing cholestatic hepatitis C or other complications. Treatment was often 
ineffective, resulting in accelerated graft loss and death, as confirmed in this analysis. DAAs, by contrast, 
are well tolerated and recommended for all actively infected patients.7,9,28
 The availability of effective posttransplant HCV treatment allows LT and KT recipients to time 
treatment to achieve the greatest benefit.
 Based on national data and 
early follow-up, there is a consistent pattern of improved outcomes in LT recipients with HCV treated 
with DAAs. In KT recipients, treatment of HCV is less common than in LT recipients. However, a similar 
protective effect is noted in D+/R+ KT recipients, who have reduced mortality and, likely, graft loss if 
they receive posttransplant DAAs. Access to these expensive medications however appears limited, as 
less than 20% of D+/R+ LT and KT recipients receive them, and DAA treatment rates appear to be even 
lower among privately insured patients.  
24,29 Pretransplant patients who are pre-cirrhotic or who have 
well-compensated disease may benefit from early HCV treatment with stabilization or regression of 
chronic liver disease, potentially avoiding LT entirely. Ahmed et al. recently reported a Markov analysis 
comparing delayed or immediate HCV treatment among patient waiting for LT.30 The benefit of HCV 
treatment varied according to clinical condition. Among patients with decompensated liver disease, pre-
LT treatment was associated with improved survival (9.3 vs. 8.7 quality-adjusted life-years) but higher 
costs ($304,800 USD vs. $283,789 USD). Results were sensitive to MELD score at evaluation, such that 
pre-LT treatment was of less benefit to patients with greater decompensation. Decompensated patients 
may be further disadvantaged by pre-LT treatment, as the availability of HCV-infected donor organs has 
historically been significantly greater, allowing earlier transplant. Among patients with stable liver 
disease who undergo transplant due to hepatocellular carcinoma, immediate HCV treatment was 
associated with a gain of 11.5 quality-adjusted life-years vs. 10.4 for delayed treatment; however, health 
care expenditures were increased by $82,000 USD per patient. Our data suggest that HCV treatment 
after transplant is no longer associated with a decrement in graft or patient survival, and may in fact be 
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until after LT may be clinically and economically beneficial, provided they have access to DAAs after 
transplant. 
 Dialysis patients infected with HCV are frequently encouraged to seek DAA treatment before 
transplant despite demonstrated efficacy of DAA in the posttransplant setting.13,31 In recipients with 
available, compatible live donors, this strategy can be justified as it allows viral clearance prior to 
transplant, thereby avoiding potential post-transplant drug-drug interactions and mitigating risk of any 
early HCV-related complications, for example new onset diabetes. However, patients who are waiting 
for deceased donor organs may delay HCV treatment until after transplant to allow greater access to 
HCV+ donor organs, which is associated with a marked reduction in expected waiting times.32
 The cost of HCV therapy with DAAs increased markedly compared with interferon and ribavirin. 
The cost of care is further increased for HCV patients with co-existing organ dysfunction. Patients with 
chronic kidney disease or ESRD who require HCV treatment incur four-fold higher per member per 
month costs than HCV patients without ESRD ($5481 USD vs. $1922 USD p<0.001). Despite these high 
costs, DAA treatment in the majority of patients has been found to be generally cost effective, with 
some regimens characterized as cost saving in the non-transplant population.
 
Importantly, these data are the first to suggest improved patient and allograft survival among HCV+ KT 
patients who are treated with DAAs early post-transplant, yet less than 15% of patients who receive a 
HCV D+ organ received timely DAA treatment. 
33,34 While early treatment 
regimens, such as those identified in this data set, were very expensive, competition from newly 
released agents has dramatically reduced the cost of treatment in an effort to increase market share. 
Treatment costs have also been reduced after shorter durations of care and have been demonstrated to 
be equally effective. A recent meta-analysis assessing the cost effectiveness of pretransplant treatment 
revealed that 71% of analyses found second-generation DAAs to be cost saving and 22% cost effective, 
while only 7% were not cost effective. Further savings may be expected through reduced graft loss and 
need for retransplantation (LT) and HCV related kidney disease. Because use of kidneys from HCV-
infected donors can markedly reduce wait times for transplant for HCV-infected kidney candidates, the 
cost-saving realized by a shorter dialysis burden in these patients must be accounted for as well, 
especially in regions associated with lengthy waiting times.35 It is therefore unclear why access to 
treatment with DAAs should be limited for transplant recipients, who are even more likely to benefit 
from treatment than dialysis patients.24,36
 This analysis has several key limitations. First, we lack information regarding viral load and 
genotype in both the pre- and posttransplant setting. Therefore, it is impossible to determine 
definitively which patients were actively infected at the time of transplant. This is particularly important 
in the current era, as HCV seropositivity in the absence of a positive NAT is consistent with virological 
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account for the lower rate of utilization of HCV treatment in the post-DAA era among D-/R+ recipients. 
Second, the price of HCV medications has fallen since 2016 as new medications have been developed 
and marketed. This competition has resulted in somewhat lower costs for treatment regimens than 
reported in this analysis. Therefore, the reduced treatment access for privately insured patients that we 
found may have improved, as insurance companies start to develop new policies relating to DAAs. Third, 
despite our assembling the largest cohort reported of treatment in HCV+ recipients, the number of 
presumptively viremic patients (D+/R+) is still limited in this national study. This may limit inferences 
about the impact of treatment and comparisons of treatments. Additional data with longer periods of 
follow up may provide important insight into the benefits of these treatments. Finally, among KT 
patients, the severity of HCV-related liver disease, an important outcome determinant, was unknown. 
However, in this large-scale analysis, it is unlikely to have differed between eras. 
 In conclusion, HCV treatment patterns have changed with the introduction of highly effective 
DAAs. Fewer HCV D-/R+ LT patients are treated in the posttransplant setting, as many may have been 
treated prior to transplant, while rates have increased for D+/R+ patients. In contrast to the reduced 
survival observed in LT patients treated in the pre-DAA era, HCV treatment with DAAs was not 
associated with poor outcomes in D+/R+ HCV+ LT recipients. Future studies capturing larger samples 
may demonstrate improved survival following DAA treatment. In KT patients, HCV treatment remains 
rare, but is more common in the DAA era and appears to improve outcomes in HCV+ KT recipients. 
Finally, DAAs were associated with a 10-fold increase the cost of HCV treatment after LT and KT 
compared with medications in the pre-DAA era. These data suggest that patients with private insurance 
have reduced access to DAAs, which may result in higher rates of graft failure and death in patients who 
receive HCV+ donor organs or remain viremic at the time of transplant. Further study is needed to 
determine the optimal time and treatment strategy for transplant candidates and recipients infected 
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Figure Legend 
Figure 1: (A) Incidence of HCV treatment after liver transplant, by donor-recipient serostatus and DAA 
era. (B) Incidence of HCV treatment after kidney transplant. 
 
Figure 2: (A) Incidence of HCV treatment after liver transplant in the pre-DAA era, by donor-recipient 
serostatus and payer. (B) Incidence of HCV treatment after liver transplant in the post-DAA era, by 
donor-recipient serostatus and payer. (C) Incidence of HCV treatment after kidney transplant in the 
pre-DAA era, by donor-recipient serostatus and payer. (D) Incidence of HCV treatment after kidney 
transplant in the post-DAA era, by donor-recipient serostatus and payer. 
 
Figure 3: (A) HCV D+/R+ liver recipient survival, by DAA era. (B) HCV D+/R+ kidney recipient survival, 
by DAA era. 
 
Figure 4: (A) HCV+ liver recipient relative risks of death and graft loss, by DAA era. (B) HCV+kidney 
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Table 1. HCV Positive Liver and Kidney Transplant Recipient Treatment Patterns  
     Liver Pre-DAA HCV D+/R+ HCV D-/R+ HCV D-/R- HCV D+/R- 
Total subjects 1,132 14,640 20,864 0 
PCD eligibility at Tx 926 11,348 15,902 0 
1 year PCD eligibility post-Tx 985 12,488 18,433 0 
HCV Rx:  3 months post-Tx 3 98 3 0 
HCV Rx: 1 year post-Tx 59 820 29 0 
HCV Rx: post-Tx  335 3,907 153 0 
Listing to Tx in days (Mean) 303 282 225 NA 
 
Liver Post-DAA     
Total subjects 1,166 6,254 14,320 133 
PCD eligibility at transplant 890 4,908 10,716 85 
1 year PCD eligibility post-Tx 483 3,183 6,071 47 
HCV Rx:  3 months post-Tx 47 176 6 1 
HCV Rx: 1 year post-Tx 155 614 26 5 
HCV Rx: post-Tx  181 793 31 11 
Listing to Tx in days (Mean) 328 336 241 315 
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Kidney Pre-DAA HCV D+/R+ HCV D-/R+ HCV D-/R- HCV D+/R- 
Total subjects 1,377 3,173 95,715 232 
PCD eligibility at transplant 1,066 2,480 75,378 184 
1 year PCD eligibility post-Tx 1,256 2,925 89,704 212 
HCV Rx:  3 months post-Tx 0 2 4 0 
HCV Rx: 1 year post-Tx 11  9 6 1 
HCV Rx: post-Tx  215 298 77 12 
Listing to Tx in days (Mean) 395  826 708 411 
     
Kidney Post-DAA     
Total subjects 1,083 1,608 54,412 273 
PCD eligibility at transplant 852 1,247 42,892 157 
1 year PCD eligibility post-Tx 482 756 26,383 82 
HCV Rx:  3 months post-Tx 19  19 2 1  
HCV Rx: 1 year post-Tx 144 82 13 11 
HCV Rx: post-Tx  181 119 25 11 
Listing to Tx in days (Mean) 396 871 749 384 
 
Abbreviations: D/R; donor/recipient hepatitis status; DAA, direct acting antiviral; HCV, 
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Figure 4B. 
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